tirzepatide / niacinamide injection We are pleased to announce that we are expanding our Weight Management and Longevity offerings. Consider the in 4mL, a GIP and GLP-1 Receptor Agonist, for a variety tirzepatide / niacinamide injection Tirzepatide

Pool of Placebo-Controlled Trials The data in Table 1 are derived from 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin) in patients with type 2 diabetes [see Clinical Studies (14)]

Same peak height

The STEP 1 trial (Wilding et al., The Lancet, 2021) showed an average weight loss of 14.9% over 68 weeks versus 2.4% in the placebo group a landmark result that established semaglutide as the benchmark for GLP-1 weight loss

Specifically, Saxenda is indicated for chronic weight management in obese adults (BMI 30) or those merely overweight with a BMI 27 and a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes